JP2025503701A - Ｆａｂ断片の噴霧 - Google Patents

Ｆａｂ断片の噴霧 Download PDF

Info

Publication number
JP2025503701A
JP2025503701A JP2024541983A JP2024541983A JP2025503701A JP 2025503701 A JP2025503701 A JP 2025503701A JP 2024541983 A JP2024541983 A JP 2024541983A JP 2024541983 A JP2024541983 A JP 2024541983A JP 2025503701 A JP2025503701 A JP 2025503701A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
less
galectin
domain
fab fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503701A5 (https=
JPWO2023139090A5 (https=
Inventor
ヒューゼ‐ヴルク ナタリー
ヴァン デール ウォニング セバスチャン
ペルシエ ジャン‐ミシェル
Original Assignee
アルジェニクス ビーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルジェニクス ビーブイ filed Critical アルジェニクス ビーブイ
Publication of JP2025503701A publication Critical patent/JP2025503701A/ja
Publication of JP2025503701A5 publication Critical patent/JP2025503701A5/ja
Publication of JPWO2023139090A5 publication Critical patent/JPWO2023139090A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024541983A 2022-01-18 2023-01-18 Ｆａｂ断片の噴霧 Pending JP2025503701A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200592 2022-01-18
GB2200592.0 2022-01-18
PCT/EP2023/051073 WO2023139090A1 (en) 2022-01-18 2023-01-18 Nebulization of fab fragments

Publications (3)

Publication Number Publication Date
JP2025503701A true JP2025503701A (ja) 2025-02-04
JP2025503701A5 JP2025503701A5 (https=) 2026-01-19
JPWO2023139090A5 JPWO2023139090A5 (https=) 2026-01-19

Family

ID=85036924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541983A Pending JP2025503701A (ja) 2022-01-18 2023-01-18 Ｆａｂ断片の噴霧

Country Status (10)

Country Link
US (1) US20250059284A1 (https=)
EP (1) EP4466009A1 (https=)
JP (1) JP2025503701A (https=)
KR (1) KR20240133723A (https=)
CN (1) CN118434440A (https=)
AU (1) AU2023210422A1 (https=)
CA (1) CA3236113A1 (https=)
IL (1) IL314365A (https=)
MX (1) MX2024007659A (https=)
WO (1) WO2023139090A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
US20250059284A1 (en) 2025-02-20
WO2023139090A1 (en) 2023-07-27
CA3236113A1 (en) 2023-07-27
KR20240133723A (ko) 2024-09-04
IL314365A (en) 2024-09-01
AU2023210422A1 (en) 2024-05-23
MX2024007659A (es) 2024-07-04
EP4466009A1 (en) 2024-11-27
CN118434440A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
JP7079844B2 (ja) 高濃度抗ｃ５抗体製剤
RU2731644C2 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CN101668773B (zh) 人工程化抗b因子抗体
KR101782203B1 (ko) 동결건조 및 수성 항-cd40 항체 제제
CA2787718C (en) Methods and compositions for the preparation of aerosols
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
CN105944100B (zh) 针对组织因子途径抑制剂(tfpi)的单克隆抗体
EA038332B1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
JP7843248B2 (ja) ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
US20230201120A1 (en) Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof
EA037487B1 (ru) Биофармацевтические композиции
US20250059284A1 (en) Nebulization of fab fragments
HK40107259A (zh) Fab片段的雾化
EA050653B1 (ru) НЕБУЛИЗАЦИЯ Fab-ФРАГМЕНТОВ
EP3677280A1 (en) Polypeptide and antibody bound to polypeptide
TW202529811A (zh) 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
HK40096185A (zh) 生物医药组合物
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
WO2024250605A1 (zh) 结合组织因子途径抑制物的抗体及其用途
HK40059623B (zh) 包含抗il-5抗体的药物组合物及其用途
HK1251867B (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260106